introduction Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder, which was initially described over half a century ago [1] . Both MCD and Kaposi's sarcoma (KS) are associated with infection with human herpesvirus (HHV)-8, also known as Kaposi's sarcoma-associated herpesvirus [2] . Use of highly active antiretroviral therapy (HAART) in established market economies has led to regression of KS in individual cases and a marked fall in incidence, attributed to improved immune function associated with HAART [3, 4] . While MCD is thought to occur with increased frequency in HIV, there are no publications that address its incidence and current information available is limited to recently published case series [5] [6] [7] . The lack of data may relate to the fact that this unusual lymphoproliferation is not recorded in cancer registries.
We therefore investigated the incidence of HIV-associated MCD over time and compared this with the incidence of HIV-associated KS, which has decreased since the introduction of HAART. We have prospectively collected data on KS and MCD as part of the prospective HIV database at the Chelsea and Westminster Hospital, including >50 000 years of patient follow-up [8] . Univariate and multivariate analyses were carried out to investigate the influence of age, race, immune suppression and HAART on the incidence of the disease. Finally, we measured plasma levels of HHV-8 DNA in HIV patients with newly diagnosed MCD, KS and lymphomas. These were compared with HIV-positive controls that had not been previously diagnosed with these diseases. age, immune parameters, AIDS-defining illnesses, HAART use and the occurrence of other HIV-related diseases including MCD. HIV-positive patients are seen at regular intervals for clinical assessment. We have calculated the incidence of MCD and KS (expressed as cases/10 000 years of patient follow-up) and have investigated specific factors, which may influence their incidence. HAART was defined as use of three antiretrovirals in accordance with published guidelines [9] (dual nucleosides alone are not considered HAART). By investigating the incidence of biopsy-proven MCD and KS during three specific time intervals: pre-HAART (up to 1996), early HAART (the first 5 years of HAART was available 1997-2001) and later HAART (where HAART had been widely available for at least 5 years 2002-2007), we aimed to establish whether the incidence of these diseases is changing. Data were extracted from our prospective computerised database in February 2008 and plasma HHV-8 DNA levels were measured as previously described [10] .
Person-days of follow-up were converted to person-years at risk (PYAR). PYAR was measured from entry into the cohort to death, end of study period or the development of HIV-MCD or HIV-KS. In order to keep the coefficient of the PYAR constant, this was log transformed and used as the offset in the Poisson regression before analysis using the Genmod procedure in SAS version 9.1 with log e link and Poisson error distributions. This fits generalised linear models allowing time-dependent measures of probability.
Median and interquartile ranges were used to create unbiased categorical data. A separate category was created for all variables with missing data which ensured no degrees of freedom were lost when building multivariate models. All variables found to approach significance (P < 0.2) in univariate log-linear models were then used to build a multivariate model which allowed the risk of a particular prognostic variable to be assessed while controlling for the others in the model. The final multivariate model presented was tested for its distributional assumptions using Cox Snell residual plots and adjusted for possible confounding or residual effects. As the missing categories comprised <3% of the data and therefore had wide confidence intervals (CIs), the presented graphs exclude point estimates of missing data categories. All P values presented are two sided.
We investigated the effect of age, gender, a prior AIDS diagnosis, HAART use [including a separate analysis investigating three specific classes of antiretroviral drug individually: protease inhibitors (PIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs)], nadir CD4 cell count and duration of known HIV infection (>10 versus <10 years of HIV) on the risk of developing MCD using univariate and multivariate analyses. Appropriate ethical approval specifically for this study was obtained.
results From a cohort of 10 997 HIV-positive patients (Tables 1 and  2) , with 56 202 years of follow-up, we calculated the incidence of KS and MCD expressed as events per 10 000 patient-years of follow-up. To date, 2337 (21.3%) of the cohort have died and 649 (5.9%) have been lost to follow-up. All KS and MCD cases were histologically proven and all cases of MCD were plasmablastic variants which stained positive for the HHV-8 latent nuclear antigen (LANA).
As expected, the incidence of KS, which decreased drastically in the early-HAART era has now levelled off (Tables 1 and 2 , Figure 1 ). KS incidence was higher among men and those with a prior AIDS diagnosis, while inversely related to nadir CD4 count and HAART use.
The incidence of MCD measured 4.3/10 000 patient-years (95% CI 2.7-6.4) during the entire study period. The incidence in the pre-HAART (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) , early-HAART (1997) (1998) (1999) (2000) (2001) and later HAART (2002-2007) eras were 2.3 (95% CI 0.02-4.2), 2.8 (95% CI 0.9-6.5) and 8.3 (95% CI 4.6-12.6), respectively, representing a statistically significant increase over time (P < 0.05) (Tables 1 and 2, Figure 1) .
Neither a prior AIDS diagnosis nor gender influence the incidence of MCD in univariate or multivariate analyses (P > 0.05 for each). The significant variables in multivariate analysis associated with an increased risk of MCD (Table 3) include a high nadir CD4 cell count, increased age, non-Caucasian race, shorter HIV duration and no previous exposure to HAART (P < 0.01 for each).
We further investigated the association of HAART and a decreased risk of MCD, by studying the exposure to the three main classes of drugs (PI, NNRTI and NRTI) separately in a further multivariate model (Table 4) . Results showed that only the NRTIs were associated with a decreased risk of MCD.
The plasma HHV-8 DNA levels in the newly diagnosed MCD patients were measured and compared with HIV patients with newly diagnosed KS, lymphoma (both non-Hodgkin's lymphoma and Hodgkin's lymphoma) and HIV-positive controls without these diseases. A significantly higher proportion of MCD patients had detectable plasma HHV-8 viraemia at diagnosis (25 of 30, 83.4%) compared with KS (26 of 73, 35.6%), lymphoma (2 of 74, 3%) or HIV-positive controls (0 of 53, 0%) (v 2 test, P = 0.0001). Furthermore, the plasma levels of HHV-8 DNA in patients with detectable levels were higher in individuals at MCD diagnosis (median 41 000 copies/ml) than at KS diagnosis (median 3500 copies/ml) (Mann-Whitney U-test, P < 0.0001).
discussion
To our knowledge, this is the first study to investigate the incidence of HIV-associated MCD. The results show that original article Annals of Oncology the incidence is increasing in the HAART era. Further investigation with multivariate analysis showed that comparatively well-preserved immune function, increased age, African race, a short known duration of HIV infection and no HAART use all predisposed to the development of MCD. This is in stark contrast to KS. Therefore, although both KS and MCD are linked to HHV-8, these data suggest that immunosuppression per se predisposes to the development of KS, but not MCD. This is supported by recent in vitro data, in which MCD was not associated with a lack of HHV-8-specific CD8+ T cells or with specific limitations of their functional profile [11] .
Alternatively, more recent HIV infection and/or increasing age may alter the biology of HHV8, resulting in suboptimal or dysregulated immune responses such as the intense activation of cytokines and inflammatory markers seen in MCD [5, 7, 12] . This may in turn be dependent on relatively well-preserved immune function. These findings may explain why, unlike KS, the incidence of MCD is increasing with calendar period studied, as the immune function of the cohort overall improves in the HAART era.
In this work, we also showed that plasma levels of HHV-8 were higher in HIV-seropositive individuals with MCD Annals of Oncology original article compared with KS. Previous work has shown that in MCD, unlike KS, lytic rather than latent HHV-8 viral proteins are expressed [13] . Therefore, we speculate that HHV-8 is handled in a different manner in MCD than in KS, and the development of MCD is associated or even reliant on some form of interaction between HHV-8 and a relatively well preserved of immune system. It should be remembered that HHV-8 status is dependent on a number of factors, including number of sexual partners, cigarette smoking and alcohol consumption [14, 15] . These factors cannot be further investigated in our database as they were not prospectively recorded and this must be taken into consideration when interpreting these results. It is not clear why HAART use (specifically NRTIs) protects against the development of MCD in the multivariate model.
The numbers of patients receiving PIs and NNRTIs were comparatively small and almost all patients were taking NRTIs simultaneously, which may account for the lack of protection by these classes of drugs. Nevertheless, it is of interest that the PIs did not reduce the risk of MCD as they have been shown to possess specific antiangiogenic properties [16] . These findings require further investigation, especially as the incidence appears to be increasing in the HAART era.
The observation that Caucasians have a reduced risk of MCD may relate to racial differences in the seroprevalence of HHV-8 in the cohort. Other factors, which could explain the rising incidence of HIV-associated MCD, include an increased awareness of MCD by health care professionals or an increase in the number of biopsies undertaken in individuals with lymphadenopathy and inflammatory signs or symptoms in whom the disease is suspected. Additionally, it is not known whether the prevalence of HHV-8 has increased in the cohort and whether our findings are generalisable across HIV cohorts. 
